GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue

GoodRx faces revenue stagnation with Q1 2026 sales declining 4.4% year-over-year to $194 million, though its Pharma Direct business showed encouraging 82% growth. Meanwhile, Hims & Hers Health demonstrates strong momentum with 59% year-over-year revenue growth in Q4 2025 and 13% subscriber growth, capitalizing on rising healthcare costs and limited access to primary care physicians.

05/10/2026, 8:24 AM • The Motley Fool

GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market

GoodRx Holdings shares rose 2.69% as the company expanded access to Novo Nordisk's Wegovy HD, a higher-dose GLP-1 treatment for self-pay patients priced at $399 per month. The expansion reflects growing demand for GLP-1 obesity treatments and GoodRx's efforts to simplify medication access. The company also recently expanded access to Eli Lilly's oral GLP-1 medication Foundayo and Zepbound.

04/15/2026, 1:25 PM • Benzinga

Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings.

Amazon has entered the GLP-1 weight loss drug market by offering Novo Nordisk's Wegovy pill through its pharmacy service at competitive prices ($25-$149 per month). This move could significantly impact competitors like Hims & Hers, WW International, and GoodRx, as Amazon leverages its 200 million Prime members and e-commerce platform. While the pill form is expected to drive overall GLP-1 adoption, Amazon's scale and reach pose a competitive threat to specialized GLP-1 retailers.

02/05/2026, 8:15 PM • The Motley Fool

Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost

Novo Nordisk launched its Wegovy weight loss pill in US pharmacies in December 2025 with competitive pricing starting at $149/month for self-pay patients. The pill demonstrated 17% average weight loss versus 3% for placebo. It's available through major retailers including CVS and Costco, as well as telehealth providers. Despite the positive product launch, NVO stock remains down 35.61% over the past year and trades 8.4% below its 200-day moving average.

01/05/2026, 12:23 PM • Benzinga

Novo Nordisk Leans Into Affordability Amid Rising Competition

Novo Nordisk announced a price reduction for Wegovy and Ozempic, offering a $199/month introductory rate for new self-pay patients, and lowering the standard monthly price from $499 to $349 to improve medication accessibility.

11/17/2025, 1:01 PM • Benzinga

Telepharmacy Market Size to Reach US$ 21.89 Billion By 2032, Bridges Rural–Urban Healthcare Gap and Expands Digital Pharmacy Access | S&S Insider

The telepharmacy market is projected to grow from $10.06 billion in 2024 to $21.89 billion by 2032, with a 10.23% annual growth rate. The market is driven by technological advancements, reducing healthcare disparities, and expanding digital pharmacy access, particularly in rural areas.

09/18/2025, 10:00 AM • GlobeNewswire

Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets

GoodRx announced a collaboration with Novo Nordisk to offer Ozempic and Wegovy pens at $499/month for eligible self-paying patients, expanding medication access and meeting growing demand for GLP-1 medications.

08/18/2025, 11:36 AM • Benzinga